Is voice therapy an effective treatment for dysphonia? A randomised controlled trial by MacKenzie, K. et al.
Papers
Is voice therapy an effective treatment for dysphonia?
A randomised controlled trial
Kenneth MacKenzie, Audrey Millar, Janet A Wilson, Cameron Sellars, Ian J Deary
Abstract
Objectives To assess the overall efficacy of voice
therapy for dysphonia.
Design Single blind randomised controlled trial.
Setting Outpatient clinic in a teaching hospital.
Participants 204 outpatients aged 17›87 with a
primary symptom of persistent hoarseness for at least
two months.
Interventions After baseline assessments, patients
were randomised to six weeks of either voice therapy
or no treatment. Assessments were repeated at six
weeks on the 145 (71%) patients who continued to
this stage and at 12›14 weeks on the 133 (65%)
patients who completed the study. The assessments at
the three time points for the 70 patients who
completed treatment and the 63 patients in the group
given no treatment were compared.
Main outcome measures Ratings of laryngeal
features, Buffalo voice profile, amplitude and pitch
perturbation, voice profile questionnaire, hospital
anxiety and depression scale, clinical interview
schedule, SF›36.
Results Voice therapy improved voice quality as
assessed by rating by patients (P = 0.001) and rating by
observer (P < 0.001). The treatment effects for these
two outcomes were 4.1 (95% confidence interval 1.7
to 6.6) points and 0.82 (0.50 to 1.13) points.
Amplitude perturbation showed improvement at six
weeks (P = 0.005) but not on completion of the study.
Patients with dysphonia had appreciable
psychological distress and lower quality of life than
controls, but voice therapy had no significant impact
on either of these variables.
Conclusion Voice therapy is effective in improving
voice quality as assessed by self rated and observer
rated methods.
Introduction
Many patients have transient, self limiting changes in
voice, but those who have been hoarse for more than
three weeks need specialist assessment to exclude
underlying laryngopharyngeal pathology. Once condi›
tions that need surgery have been excluded, patients
are usually referred to a speech and language therapist
for voice therapy. Up to 40 000 patients with dysphonia
are referred for voice therapy annually in the United
Kingdom.1 At the time of referral, many patients with
vocal dysfunction have entered a vicious cycle in which
psychological factors exacerbate voice pathology and
poor voice quality adversely affects psychological
wellbeing.2–9 The relation between these factors is com›
plex, and the relative influence of each factor varies
from individual to individual.
No study has yet examined the overall effectiveness
of voice therapy for dysphonia in terms of either
changes in voice quality or changes in psychological
distress or laryngoscopic findings. We aimed to
examine the efficacy of voice therapy in patients with
dysphonia and to identify those patients for whom
voice therapy might be most beneficial.
Participants and methods
We recruited consecutive outpatients attending the
department of otorhinolaryngology and head and
neck surgery of Glasgow Royal Infirmary with a
primary complaint of dysphonia (hoarseness) present
for a minimum of two months and without any
relevant organic pathology (for example, polyp,
papilloma, tumour, vocal cord palsy) or need for
surgery.
The inclusion criteria were age greater than 16
years, motivation to resolve the voice problem, and
willingness to enter into regular voice therapy sessions.
The exclusion criteria were previously treated dyspho›
nia, neurological disease, or upper aerodigestive tract
malignancy; marked hearing impairment; acid reflux;
multiple medical complaints; professional voice user
requiring urgent intervention; puberphonia; and
transsexual conflict.
The 204 patients (51 men, 153 women) who gave
informed consent for inclusion were new referrals
typical of patients referred for voice therapy. At entry
to the study, 100 patients were randomised to voice
therapy and 104 to no treatment. By completion of the
study 12›14 weeks later, about a third of participants
had dropped out or been excluded, leaving 70 patients
in the treatment group and 63 patients in the observa›
tion group (figure). This attrition was mostly a result of
patients defaulting. In addition to failure to reattend,
some patients failed to complete all self report
questionnaires, notably where these had to be returned
by post, despite the issuing of prepaid envelopes.
Another subgroup omitted a number of items within
questionnaires. The voice therapy and no treatment
groups were not significantly different in terms of
Editorial by Carding
Department of
Otorhinolaryngology
and Head and Neck
Surgery, Glasgow
Royal Infirmary,
Glasgow G31 2ER
Kenneth
MacKenzie
consultant
otolaryngologist
Audrey Millar
research scientist
Department of
Speech and
Language Therapy,
Glasgow Royal
Infirmary
Cameron Sellars
senior speech and
language therapist
Department of
Otorhinolaryngology
and Head and Neck
Surgery, University
of Newcastle,
Newcastle upon
Tyne NE7 7DN
Janet A Wilson
professor of
otolaryngology
Department of
Psychology,
University of
Edinburgh,
Edinburgh EH8 9JZ
Ian J Deary
professor of
differential psychology
Correspondence to:
K MacKenzie
kmk2x@clinmed.
gla.ac.uk
BMJ 2001;323:1–6
1BMJ VOLUME 323 22 SEPTEMBER 2001 bmj.com
either rate of attrition (30% in the therapy group, 39%
in the no treatment group) or characteristics of
patients who dropped out (sociodemographic vari›
ables or baseline voice or psychological variables).
There is thus no evidence that the attrition will have
introduced bias. Analysis of each outcome was
conducted only on patients with complete data.
Measures
Pathophysiology—An otolaryngologist (KMacK) used a
flexible nasolaryngoscope (Olympus ENF 3) to assess
four features—nodule formation, laryngitis, glottic
escape, and hyperfunction of the laryngeal
musculature—on a four point (0›3) rating scale.
Although stroboscopic findings may facilitate the diag›
nosis of subtle laryngeal dysfunction, we decided not to
use our stroboscope because we wanted the study to
reflect routine clinical practice throughout the United
Kingdom.
Voice quality—A digital tape recording of the
patient’s reading of the phonetically balanced “rain›
bow” passage (a standard paragraph used in voice
assessment) was analysed by a speech and language
therapist blind to treatment group.10 Ten aspects of
voice, including laryngeal tone, pitch, and resonance,
were rated 0›5 on the Buffalo voice profile scale,11 of
which the “overall rating” item was chosen as the key
observer rated variable. The same therapist also
extracted two key objective measures of voice quality—
“jitter” (pitch perturbation) and “shimmer” (amplitude
perturbation)—by using the Computerised Speech
Laboratory (model 4300B; Kay Elemetrics Corp, NJ).
The higher the score on these two variables the more
dysphonic the voice. Patients rated their own voice
quality using the validated vocal performance ques›
tionnaire,12 with five point scoring on 12 items (1›5,
5 = worst). The total voice profile questionnaire score
was the key self reported outcome measure.
Psychological measures—The hospital anxiety and
depression scale is a self completed questionnaire
which assesses recent anxiety and depression and pro›
vides an overall score for each.13 The revised clinical
interview schedule was conducted by a trained
psychologist blind to the treatment group.14 The inter›
viewer rated 14 aspects of non›psychotic psychiatric
disturbance. The clinical interview schedule’s overall
distress score and the hospital anxiety and depression
scale’s anxiety score were the key outcome measures of
psychological distress.
Quality of life was assessed by the SF›36, an eight
dimension, extensively validated assessment of general
health status.15
Intervention
Baseline data were recorded after eligibility had been
assessed and consent had been obtained by the laryn›
gologist. The participants were then seen by one
speech and language therapist (CS), who obtained a
number for random allocation of the participant to
either a course of voice therapy or a period of observa›
tion. Computer generated random numbers produced
Voice therapy delivered over six
weeks, and then all baseline
assessments repeated except
clinical interview schedule (n=100)
Period of observation over six
weeks, and then all baseline
assessments repeated except
clinical interview schedule (n=100)
All baseline assessments repeated
after an observation period of
6-8 weeks
All baseline assessments repeated
after an observation period of
6-8 weeks
Patients presenting to otorhinolaryngology clinic with dysphonia (n=664)
Not randomised. Did not satisfy inclusion criteria (n=440)
Baseline assessment data recorded (n=204)
Withdrawn owing to defaulting
or refusal (n=30)
Withdrawn owing to defaulting
or refusal (n=41)
Completed (n=70) Completed (n=63)
Randomisation
Flow chart of study
Treatment protocol
The voice therapy group initially comprised 100
patients; eight patients were excluded from the study
before therapy. These exclusions occurred for a range
of reasons, most of which (for example, dementia) only
emerged at the follow up appointment. Two patients
withdrew from the study after the first visit. In addition
to the eight patients who were excluded after
allocation to the therapy group (two of whom
withdrew), eight patients failed to attend the first
therapy appointment. A further 10 patients defaulted
during therapy. This meant that 74 patients completed
a course of voice therapy, 70 of whom had complete
data sets.
Participants entering the treatment group of the
study were given an appointment at which a routine
voice history was taken. A recording of the “rainbow”
passage was taken for possible reference in therapy. In
line with current practice,16 and depending on clinical
circumstances, a number of patients (11 out of the 74
who completed treatment) received advice on good
vocal hygiene and optimal voice production and did
not proceed to a fuller programme of voice therapy,
although this option remained open to them until
attendance for the second visit. The remainder of the
patients (63) underwent voice therapy for up to six
sessions (eight sessions in one case). The treatment
sessions lasted 45›60 minutes. The number of sessions
needed and the type of treatment carried out were
determined heuristically, depending partly on the
nature of the symptoms and partly on patients’
priorities.16 Treatment could be indirect—for example,
involving discussion of issues of vocal hygiene or of
lifestyle impinging on voice production. Equally,
patients could be invited to practise techniques related
to their vocal symptoms—for example, improving
breath support for vocal production or altering vocal
onset in favour of “softer” vocal attack. Because of the
limited possibilities for contact with patients, therapy
favouring attention to vocal symptoms predominated,
but issues were incorporated relating to possible
underlying psychological distress. Indeed, where these
were clearly the focus of concern to the patient, a
counselling approach was adopted.
The programme of voice therapy ended by mutual
agreement between the treating therapist and the
individual patient. Completion of therapy did not
imply complete recovery at that time but rather a
recognition that good vocal practice needed ongoing
attention over a sustained period beyond the contact
limits set for this project.
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in a restricted randomisation form were supplied by an
independent worker in a separate department. All
voice therapy was delivered by CS according to a pro›
tocol (see box) derived from a review of the type, form,
and frequency of voice therapy used by a substantial
sample of speech and language therapists in the
United Kingdom.16 CS was not involved in the
collection, storage, or analysis of outcome data in any
way. Equally, the details of the treatment of this group
were at no time communicated to any member of the
research assessment team involved in collecting
outcome data. After six weeks of therapy or
observation, data on pathophysiology, voice quality,
psychological status, and quality of life (with the excep›
tion of the clinical interview schedule) were recorded.
After a further 6›8 weeks, all measurements were
repeated, and the clinical interview schedule was
conducted.
Before the study, the intended number of patients
to be recruited in the treatment and non›treatment
groups was determined by assuming a medium effect
size of treatment (0.5 SD units). This is a conservative
effect size compared with that indicated in the available
literature. Also, greater than 90% power was sought
with á set at 0.05 (two tailed). The target chosen was
100 patients in each group, which offered 94% power.
At the end of the study we had data from 70 and 63
people in the two groups; with the same assumptions,
this offered 81% power.
Statistical analysis
Statistical analyses compared the mean difference in
the outcome variables between the groups with and
without treatment. We conducted separate analyses at
the end of treatment and at the later follow up. Each
analysis took into account the baseline (entry to study)
score for each of the outcome variables. We thus used
an analysis of covariance procedure with group (treat›
ment versus no treatment) as a between patients
variable; we used people’s baseline scores on the
particular variable being compared as covariates. We
used baseline values as the covariates for both the end
of treatment and follow up analyses.
Assessment of the effect of voice therapy on patho›
physiological outcomes needed a categorical
approach. We subtracted ratings for each pathophysi›
ological feature for each patient at the end of treatment
(visit 2) from those at baseline (visit 1); we also
subtracted ratings for each feature at the end of follow
up (visit 3) from those at visit 1. We then assigned
patients to a category (0, 1, or 2) according to whether
they had improved, deteriorated, or stayed the same.
We performed a series of ÷2 intergroup comparisons.
We calculated treatment effects as mean differences
at the relevant outcome (visits 2 and 3) controlled for
baseline scores in the respective measure. We used
general linear modelling (analysis of covariance) in
SPSS 9/10 to perform the analysis.
Results
As expected, most patients in both groups were
women; the groups were closely matched for age (table
1). Laryngeal features at study entry were similar in the
intervention and control patients (either in the 204
patients originally recruited or in the 145 with repeat
laryngoscopy at six weeks). Grade 2›3 (moderate to
severe) scores were uncommon for all of the four
features, and only minimal resolution of the abnor›
malities occurred between the two time points (table 1).
The groups were well matched at entry to the study
for subjective and objective voice variables (table 2).
The treatment and no treatment groups differed at
baseline only on the hospital anxiety and depression
scale anxiety scores, which were significantly higher in
the control group (t = 2.67, P = 0.008).
This difference between the treatment and no
treatment groups was evident in the original 204
randomised recruits and in the 133 patients who com›
pleted all three phases of the study. Both the treatment
and no treatment groups had high baseline scores for
anxiety on the hospital anxiety and depression scale
compared with healthy controls from the scale’s
normative reference data, though not necessarily with
other otorhinolaryngology patients.8 9 The baseline
SF›36 quality of life scores reflect a severely impaired
quality of life in both the treatment and no treatment
groups compared with other groups of patients.15
Effectiveness of voice therapy
By the end of treatment voice therapy significantly
improved self rated quality of voice as measured by the
voice profile questionnaire and the measurement of
amplitude perturbation or “shimmer” by the Compu›
terised Speech Laboratory. At follow up the patients in
the treatment group had significantly lower scores than
those in the no treatment group on the Buffalo overall
rating and the voice profile questionnaire total score.
Treatment effects (points) and 95% confidence
intervals were calculated for each of the outcome vari›
ables at both completion of treatment and completion
of follow up (tables 2 and 3). All participants with data
at baseline and follow up were included. For the voice
profile questionnaire the effect was 4.1 points (effect
size 0.54 SD). For the Buffalo scale the effect was 0.82
Table 1 Laryngoscopic data for treatment and no treatment groups at baseline and first
follow up (only those who attended at first follow up are included at baseline). Values
are numbers (percentage) of patients unless otherwise stated
No treatment (n=72) Treatment (n=73)
Baseline Follow up Baseline Follow up
No (%) female 50 (69) 56 (77)
Mean (SD) age (years) 52.0 (13.2) 50.6 (13.8)
Nodules:
0 59 (82) 62 (86) 64 (88) 68 (93)
1 9 (13) 8 (11) 7 (10) 3 (4)
2 3 (4) 2 (3) 2 (3) 1 (1)
3 1 (1) 0 0 1 (1)
Laryngitis:
0 46 (64) 46 (64) 42 (58) 43 (59)
1 20 (28) 19 (26) 19 (26) 22 (30)
2 6 (8) 7 (10) 12 (16) 8 (11)
3 0 0 0 0
Glottic escape:
0 58 (81) 62 (86) 54 (74) 61 (84)
1 13 (18) 9 (13) 16 (22) 10 (14)
2 1 (1) 1 (1) 3 (4) 2 (3)
3 0 0 0 0
Hyperfunction:
0 63 (88) 65 (90) 60 (82) 68 (93)
1 5 (7) 4 (6) 10 (14) 4 (5)
2 3 (4) 3 (4) 3 (4) 1 (1)
3 1 (1) 0 0 0
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points (effect size 0.76 SD). In conventional statistical
terminology these are medium to large effects. Voice
therapy had an effect on only one quality of life
outcome variable—mental health. This was significantly
better in the treatment group at completion of
treatment but not at completion of follow up.
To address the issue of dropout we re›ran the
analyses including all patients with data at baseline. For
patients with missing data at visit 2 or visit 3 we entered
the baseline values. This makes the conservative
assumption that there was no difference in outcome
between patients who dropped out from the treatment
and no treatment groups. On reanalyses of the
sensitivity scores, treatment effects (points), and
confidence intervals for each of the outcome measures,
the results retained their significant P values and treat›
ment effects (tables 4 and 5).
Discussion
This first randomised controlled trial of the efficacy of
voice therapy for dysphonia has shown voice therapy
to be effective in improving self rated and expert rated
quality of voice. The magnitude of the observed mean
improvements reflects clinically meaningful improve›
ments in voice quality. The minimal change in laryngo›
scopic appearances during the study reflects the fact
that many of the patients referred for non›surgical
Table 2 Mean (SD) scores for key voice and psychological variables at each visit for treatment and no treatment groups (patients
with complete data)
Test or questionnaire
Treatment No treatment
F value
Treatment effect
(points (95% CI))
No of
patients
Visit 1
(baseline) Visit 2 or 3
No of
patients
Visit 1
(baseline) Visit 2 or 3
At completion of treatment (visit 2)
Psychological distress:
HADS anxiety 67 6.3 (4.0) 5.9 (4.5) 63 8.1 (4.3) 7.7 (3.9) 0.71 (P=0.402) 0.39 (−0.53 to 1.31)
HADS depression 67 3.7 (3.5) 3.6 (3.7) 63 4.2 (3.3) 4.2 (3.1) 0.38 (P=0.540) 0.25 (−0.55 to 1.05)
CIS total score 67 7.0 (6.9) 62 8.6 (8.2)
Voice:
Buffalo overall rating* 74 2.9 (1.1) 2.3 (0.93) 69 2.9 (1.0) 2.5 (0.93) 2.33 (P=0.130) 0.21 (−0.01 to 0.49)
Pitch perturbation† 67 3.2 (2.4) 2.8 (1.5) 57 2.4 (1.4) 2.8 (1.5) 0.97 (P=0.326) 0.25 (−0.25 to 0.74)
Amplitude perturbation† 67 6.0 (4.2) 4.5 (2.6) 57 5.0 (3.3) 5.7 (3.8) 8.03 (P=0.005) 1.6 (0.47 to 2.63)
VPQ total‡ 67 27.6 (8.0) 22.4 (5.8) 65 27.9 (7.5) 25.4 (8.1) 6.12 (P=0.015) 2.6 (0.51 to 4.63)
At completion of follow up (visit 3)
Psychological distress:
HADS anxiety 62 6.6 (4.0) 5.9 (3.8) 56 8.1 (4.0) 6.7 (4.1) 0.00 (P=0.969) 0.02 (−1.21 to 1.25)
HADS depression 62 4.2 (3.6) 3.8 (3.5) 56 4.2 (3.3) 4.3 (3.6) 1.08 (P=0.300) 0.4 (−1.3 to 0.39)
CIS total score 67 7.0 (6.9) 7.3 (8.1) 62 8.6 (8.2) 7.6 (8.8) 0.64 (P=0.424) 0.89 (−1.3 to 3.06)
Voice:
Buffalo overall rating* 70 2.9 (1.1) 2.2 (1.0) 63 2.8 (1.0) 3.0 (1.0) 26.50 (P<0.001) 0.82 (0.5 to 1.13)
Pitch perturbation† 65 3.1 (2.4) 2.7 (1.5) 54 2.4 (1.4) 2.2 (1.5) 1.58 (P=0.212) 0.35 (−0.20 to 0.89)
Amplitude perturbation† 65 5.8 (3.9) 4.1 (3.0) 54 5.1 (3.2) 4.5 (3.6) 0.90 (P=0.345) 0.57 (−0.62 to 1.77)
Score on VPQ‡ 61 28.8 (8.2) 21.6 (6.3) 57 28.0 (7.5) 25.4 (8.5) 10.96 (P=0.001) 4.14 (1.67 to 6.61)
HADS=hospital anxiety and depression scale; CIS=clinical interview schedule; VPQ=vocal performance questionnaire.
*Buffalo voice profile analysis has an “overall rating” as 1 of 10 items scored 0›5.
†The higher the score the more dysphonic the voice.
‡Maximum score=60; the higher the score the more dysphonic the voice.
Table 3 Mean (SD) scores for quality of life (SF›36) variables at each visit for treatment and no treatment groups (patients with
complete data). Higher scores indicate better health
Treatment No treatment
F value
Treatment effect
(points (95% CI))
No of
patients
Visit 1
(baseline) Visit 2 or 3
No of
patients
Visit 1
(baseline) Visit 2 or 3
At completion of treatment (visit 2)
Physical functioning 63 66.7 (32.6) 66.6 (34.0) 65 64.3 (31.0) 64.9 (30.3) 0.01 (P=0.92) 0.33 (−6.25 to 6.90)
Social functioning 63 78.0 (25.7) 81.1 (26.4) 62 70.7 (28.5) 73.9 (27.6) 0.45 (P=0.50) 2.5 (−4.89 to 9.88)
Role (physical) 63 63.1 (43.7) 59.1 (45.0) 62 54.0 (40.8) 47.9 (42.1) 0.79 (P=0.38) 5.6 (−6.94 to 18.22)
Role (emotional) 63 78.3 (38.4) 72.2 (41.0) 63 62.7 (42.4) 64.0 (42.9) 0.03 (P=0.87) 1.0 (−11.44 to 13.45)
Mental health 63 71.5 (18.1) 76.9 (18.3) 63 65.1 (19.5) 66.1 (20.1) 6.08 (P=0.02) 6.63 (1.31 to 11.95)
Energy/fatigue 63 55.3 (20.7) 59.8 (21.4) 63 48.6 (22.2) 50.8 (23.3) 2.03 (P=0.16) 3.95 (−1.54 to 9.44)
Pain 62 64.1 (28.8) 69.0 (28.5) 60 59.7 (23.1) 62.0 (30.6) 0.87 (P=0.35) 3.96 (−4.44 to 12.36)
Health perception 58 64.9 (23.4) 66.5 (25.5) 63 57.7 (23.1) 59.9 (23.5) 0.01 (P=0.93) 0.24 (−4.76 to 5.24)
At completion of follow up (visit 3)
Physical functioning 59 67.7 (31.8) 69.1 (30.2) 56 64.6 (30.5) 64.1 (30.4) 0.55 (P=0.46) 2.5 (−4.19 to 9.19)
Social functioning 58 77.4 (25.9) 78.2 (26.1) 55 74.0 (25.1) 72.9 (28.4) 0.55 (P=0.46) 3.11 (−5.18 to 11.4)
Role (physical) 60 62.5 (44.5) 61.7 (43.5) 55 50.5 (40.7) 51.4 (44.5) 0.18 (P=0.67) 2.86 (−10.34 to 16.06)
Role (emotional) 60 76.7 (39.5) 70.8 (40.1) 56 57.5 (42.9) 58.3 (45.5) 0.03 (P=0.87) 1.07 (−12.26 to 14.41)
Mental health 58 70.8 (18.6) 74.7 (17.8) 55 65.2 (19.8) 67.9 (19.7) 1.58 (P=0.21) 3.66 (−2.12 to 9.44)
Energy/fatigue 58 54.6 (20.4) 56.1 (24.6) 55 49.5 (21.2) 51.0 (23.6) 0.07 (P=0.80) 0.81 (−5.45 to 7.06)
Pain 56 62.2 (28.5) 60.7 (29.0) 56 61.3 (23.9) 55.8 (28.7) 1.04 (P=0.80) 4.29 (−4.03 to 12.6)
Health perception 55 63.2 (23.7) 65.0 (25.8) 55 58.4 (24.0) 59.3 (26.0) 0.28 (P=0.60) 1.46 (−4.02 to 6.94)
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voice therapy have, by definition, relatively normal
laryngeal appearances.
Psychological distress was not significantly reduced
as a result of treatment. Voice therapy had a significant
effect on one quality of life variable—mental health—at
the end of treatment, but this was not maintained at
follow up. A subgroup of patients remain psychologi›
cally distressed despite receiving treatment. Speech
and language therapists often use psychological
strategies but often acquire psychological training after
qualification and in what has been described as an ad
hoc manner.17 If patients with high psychological
distress could be identified by screening they could be
referred for psychological intervention, perhaps from
a clinical psychologist.18
The disconcertingly abnormal SF›36 results high›
light the importance of effective vocal communication
for an individual’s psychosocial wellbeing. Indeed, the
level of psychological morbidity may also mainly
reflect the greatly reduced quality of life in patients
with dysphonia. Such interrelations underline the
importance of a holistic treatment for reduction in
symptoms and improvement in overall functioning.
In conclusion, this study shows that voice therapy is
effective in improving self rated and observer rated
measures of voice quality. However, voice therapy does
Table 4 Mean (SD) scores for key voice and psychological variables at each visit for treatment and no treatment groups (all patients
with baseline data)
Test or questionnaire
Treatment No treatment
Sensitivity score
(F value)
Treatment effect
(points (95% CI))
No of
patients
Visit 1
(baseline)
Visit 2 or
3
No of
patients
Visit 1
(baseline) Visit 2 or 3
At completion of treatment (visit 2)
Psychological distress:
HADS anxiety 85 6.5 (4.2) 6.2 (4.4) 80 8.2 (4.2) 7.9 (4.0) 0.67 (P=0.416) 0.30 (−0.43 to 1.04)
HADS depression 85 4.1 (3.5) 4.0 (3.7) 80 4.6 (3.6) 4.5 (3.4) 0.30 (P=0.584) 0.17 (−0.46 to 0.81)
CIS total score 99 7.6 (7.5) 103 9.2 (9.3)
Voice:
Buffalo overall rating* 100 2.9 (1.0) 2.4 (1.0) 103 3.0 (1.0) 2.7 (1.0) 5.0 (P=0.03) 0.25 (0.003 to 0.47)
Pitch perturbation† 97 3.1 (2.2) 2.8 (1.6) 92 2.9 (2.2) 3.1 (2.2) 5.7 (P=0.018) 0.46 (0.008 to 0.84)
Amplitude perturbation† 97 6.1 (4.3) 5.1 (3.5) 92 6.1 (5.3) 6.5 (5.5) 11.9 (P=0.001) 1.5 (0.64 to 2.3)
VPQ total‡ 85 28.4 (9.0) 24.2 (8.3) 81 29.4 (8.9) 26.9 (9.5) 3.9 (P=0.051) 1.9 (−0.001 to 3.8)
At completion of follow up (visit 3)
Psychological distress:
HADS anxiety 85 6.5 (4.2) 6.0 (3.9) 80 8.2 (4.2) 7.2 (4.3) 0.018 (P=0.893) 0.006 (−0.88 to 1.01)
HADS depression 85 4.1 (3.5) 3.8 (3.4) 80 4.6 (3.6) 4.6 (3.8) 1.51 (P=0.221) 0.37 (−0.23 to 0.98)
CIS total score 99 7.6 (7.5) 7.6 (8.2) 103 9.2 (9.3) 8.6 (9.7) 0.63 (P=0.428) 0.58 (−2.01 to 0.86)
Voice:
Buffalo overall rating* 100 2.9 (1.0) 2.4 (1.0) 103 3.0 (1.0) 3.1 (1.0) 29.80 (P=0.000) 0.62 (0.40 to 0.85)
Pitch perturbation† 97 3.1 (2.2) 2.8 (1.6) 92 2.9 (2.2) 2.8 (2.3) 0.140 (P=0.709) 0.008 (−0.35 to 0.51)
Amplitude perturbation† 97 6.1 (4.3) 5.0 (4.0) 92 6.1 (5.3) 5.8 (5.6) 2.8 (P=0.096) 0.80 (−0.14 to 1.7)
Score on VPQ‡ 85 28.4 (9.0) 23.3 (8.3) 81 29.4 (8.9) 27.7 (9.9) 12.32 (P=0.001) 3.69 (1.61 to 5.76)
HADS=hospital anxiety and depression scale; CIS=clinical interview schedule; VPQ=vocal performance questionnaire.
*Buffalo voice profile analysis has an “overall rating” as 1 of 10 items scored 0›5.
†The higher the score the more dysphonic the voice.
‡Maximum score=60; the higher the score the more dysphonic the voice.
Table 5 Mean (SD) scores for quality of life (SF›36) variables at each visit for treatment and no treatment groups (all patients with
baseline data). Higher scores indicate better health
Treatment No treatment
F value
Treatment effect
(points (95% CI))
No of
patients
Visit 1
(baseline) Visit 2 or 3
No of
patients
Visit 1
(baseline) Visit 2 or 3
At completion of treatment (visit 2)
Physical functioning 81 65.3 (33.1) 65.2 (34.2) 81 64.7 (30.5) 65.2 (29.9) 0.040 (P=0.841) 0.53 (−4.69 to 5.75)
Social functioning 82 74.4 (26.7) 76.9 (27.6) 79 70.2 (28.6) 72.8 (27.9) 0.101 (P=0.751) 0.94 (−6.81 to 4.92)
Role (physical) 82 59.8 (43.7) 56.7 (44.5) 80 53.8 (41.5) 49.1 (42.6) 0.473 (P=0.493) 3.44 (−13.33 to 6.45)
Role (emotional) 82 70.7 (42.4) 66.0 (43.4) 81 61.1 (43.3) 62.9 (43.4) 0.389 (P=0.534) 3.10 (−6.71 to 12.90)
Mental health 82 69.9 (19.2) 74.0 (19.8) 79 64.3 (19.3) 65.1 (19.8) 4.784 (P=0.030) 4.74 (−9.01 to −0.46)
Energy/fatigue 82 53.2 (21.0) 56.7 (22.0) 79 47.2 (21.7) 48.9 (22.8) 1.611 (P=0.206) 2.81 (−7.17 to 1.56)
Pain 80 62.6 (28.9) 66.4 (28.9) 79 58.4 (25.6) 60.2 (31.0) 0.785 (P=0.377) 2.94 (−9.48 to 3.61)
Health perception 78 62.2 (23.6) 63.4 (25.4) 80 56.7 (23.4) 58.5 (23.8) 0.002 (P=0.963) 0.009 (−3.76 to 3.94)
At completion of follow up (visit 3)
Physical functioning 81 65.3 (33.1) 66.2 (32.1) 81 64.7 (30.5) 64.4 (30.5) 0.323 (P=0.570) 1.39 (−6.21 to 3.43)
Social functioning 82 74.4 (26.7) 75.0 (26.9) 79 70.2 (28.6) 69.5 (30.6) 0.533 (P=0.466) 2.22 (−8.21 to 3.78)
Role (physical) 82 59.8 (43.7) 59.1 (42.9) 80 53.8 (41.5) 54.4 (44.1) 0.007 (P=0.934) 0.40 (−9.90 to 9.11)
Role (emotional) 82 70.7 (42.4) 66.5 (42.3) 81 61.1 (43.3) 61.7 (45.1) 0.216 (P=0.643) 2.25 (−7.31 to 11.81)
Mental health 82 69.9 (19.2) 72.7 (18.9) 79 64.3 (19.3) 66.1 (19.4) 1.45 (P=0.230) 2.59 (−6.83 to 1.66)
Energy/fatigue 82 53.2 (21.0) 54.3 (24.0) 79 47.2 (21.7) 48.2 (23.5) 0.079 (P=0.780) 0.63 (−5.03 to 3.78)
Pain 80 62.6 (28.9) 61.5 (29.3) 79 58.4 (25.6) 54.6 (28.5) 1.45 (P=0.230) 3.60 (−9.51 to 2.31)
Health perception 78 62.2 (23.6) 63.5 (24.2) 80 56.7 (23.4) 57.3 (24.9) 0.315 (P=0.576) 1.08 (−4.90 to 2.73)
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not significantly affect laryngeal pathophysiology or
reduce the high levels of psychological distress that
characterise patients with dysphonia.
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What is already known on this topic
Many patients with dysphonia are treated by voice
therapy
The effectiveness of voice therapy in a diverse
group of patients is unknown
What this study adds
Voice therapy is an effective treatment for
dysphonia in terms of report by patients and
perceptual ratings by an expert
Psychological distress and reduction in general
health status are common in patients with
dysphonia but are not significantly affected by a
course of voice therapy
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